Minocycline is a broad-spectrum antibiotic of the tetracycline classification, indicating that its chemical structure consists of 4 hydrocarbon rings. The fact that minocycline has a broad-spectrum mechanism indicates that it targets a wide-range of pathogenic (Gram-positive and Gram-negative) bacteria. In fact, when compared to other tetracycline drugs, minocycline is regarded as having the “broadest spectrum” …
Mirapex (Pramipexole) is a drug that is approved by the FDA for the treatment of Parkinson’s disease and RLS (restless leg syndrome). Classified as a dopamine receptor agonist, pramipexole elicits partial or full agonism upon D3 receptors, D2 receptors (2L/2S), and D4 receptors. Interestingly, pramipexole also appears to modify mitochondrial function, and to a negligible …
Curcumin is considered a diarylheptanoid, or secondary metabolite derived from the plant turmeric (a member of the ginger family). As a diarylheptanoid, curcumin is chemically composed of two aryl groups (aromatic rings) interlinked with a chain of 7 carbon atoms. It was initially discovered by scientists Vogel and Pelletier in 1842 when they extracted and …
According to the World Health Organization (WHO), depression is projected to become the number one global disease burden by 2030. Present-day statistics suggest that depression affects over 350 million people worldwide. Among those who are depressed, seeking professional psychiatric treatment is often helpful. An estimated 66% of all individuals who seek treatment are able to …
Most pharmacological-based treatments for depression aim to increase levels of various neurotransmitters, particularly serotonin (5-HT). It is thought that approximately 2 out of 3 individuals that seek treatment with standard antidepressants such as SSRIs and SNRIs are able to attain therapeutic relief. For a certain percentage of these individuals, the benefits of using pharmaceutical interventions …
It seems as though society is on the verge of ushering in a new generation of treatment modalities for depression and other psychiatric conditions. While most people turn to pharmaceutical drugs for major depressive disorder, approximately 1 out of 3 people fail to get sufficient symptomatic relief. To make matters worse, many end up trying …
It appears as though the pharmaceutical juggernaut Eli Lilly is facing major legal backlash for failure to disclose discontinuation effects associated with their medication Cymbalta (Duloxetine). Cymbalta is an SNRI antidepressant that was approved in August 2004 for the treatment of major depression. A woman named Claudia Herrera has been making news headlines because she …